These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 14981758

  • 1. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
    Ohishi W, Shirakawa H, Kawakami Y, Kimura S, Kamiyasu M, Tazuma S, Nakanishi T, Chayama K.
    J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
    [Abstract] [Full Text] [Related]

  • 2. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
    Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Satoh J, Kobayashi M, Ikeda K, Miyakawa Y, Kumada H.
    J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
    [Abstract] [Full Text] [Related]

  • 3. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM, Kazim SN, Khan LA, Raisuddin S, Parvez MK, Guptan RC, Thakur V, Hasnain SE, Sarin SK.
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [Abstract] [Full Text] [Related]

  • 4. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
    Liang WF, Yang DH, Shen YH, Xie YJ, Zhao NF.
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
    [Abstract] [Full Text] [Related]

  • 5. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [Abstract] [Full Text] [Related]

  • 6. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
    Pan XP, Wo JE, Chen Z, Chen F, Liang WF, Liu KZ.
    Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
    [Abstract] [Full Text] [Related]

  • 7. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
    Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH.
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
    [Abstract] [Full Text] [Related]

  • 8. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H.
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [Abstract] [Full Text] [Related]

  • 9. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF.
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [Abstract] [Full Text] [Related]

  • 10. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
    Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, Benardi M, Andreone P.
    Hepatology; 2000 Nov; 32(5):1145-53. PubMed ID: 11050068
    [Abstract] [Full Text] [Related]

  • 11. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains.
    Hosseini SY, Sabahi F, Amini-Bavil-Olyaee S, Alavian SM, Merat S.
    J Virol Methods; 2006 Nov; 137(2):298-303. PubMed ID: 16962669
    [Abstract] [Full Text] [Related]

  • 12. Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)--direct sequencing method for detecting lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity.
    Ogata N, Ichida T, Aoyagi Y, Kitajima I.
    Rinsho Byori; 2003 Apr; 51(4):313-9. PubMed ID: 12747252
    [Abstract] [Full Text] [Related]

  • 13. Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis.
    Shih YH, Yeh SH, Chen PJ, Chou WP, Wang HY, Liu CJ, Lu SF, Chen DS.
    Antivir Ther; 2008 Apr; 13(4):469-80. PubMed ID: 18672526
    [Abstract] [Full Text] [Related]

  • 14. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
    Sun J, Wang Z, Ma S, Zeng G, Zhou Z, Luo K, Hou J.
    J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
    [Abstract] [Full Text] [Related]

  • 15. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C, Ajana F, Canva V, Mouton Y, Yazdanpanah Y, Wattré P, Bocket L.
    Ann Biol Clin (Paris); 2002 Mar; 60(5):581-8. PubMed ID: 12368144
    [Abstract] [Full Text] [Related]

  • 16. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.
    Amini-Bavil-Olyaee S, Hosseini SY, Sabahi F, Alavian SM.
    Int J Infect Dis; 2008 Jan; 12(1):83-7. PubMed ID: 17698384
    [Abstract] [Full Text] [Related]

  • 17. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM.
    Antivir Ther; 2006 Jan; 11(4):447-55. PubMed ID: 16856618
    [Abstract] [Full Text] [Related]

  • 18. Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids.
    Mori K, Minami M, Kirishima T, Kunimoto K, Okita M, Nakayama M, Makiyama A, Yamaoka J, Nakajima T, Yasui K, Itoh Y, Okanoue T.
    Intervirology; 2006 Jan; 49(5):274-80. PubMed ID: 16714856
    [Abstract] [Full Text] [Related]

  • 19. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection.
    Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M.
    Hepatology; 1999 Mar; 29(3):939-45. PubMed ID: 10051501
    [Abstract] [Full Text] [Related]

  • 20. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH, Lu SN, Chen CH, Wang JH, Wu CM, Hung CH, Tseng PL, Hu TH, Changchien CS, Lee CM.
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.